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Effort thrombosis, or Paget-Schroetter Syndrome, refers to axillary-subclavian vein thrombosis 
associated with strenuous and repetitive activity of the upper extremities. Anatomical abnormalities 
at the thoracic outlet and repetitive trauma to the endothelium of the subclavian vein are key factors 
in its initiation and progression. The role of hereditary and acquired thrombophilias is unclear. The 
pathogenesis of effort thrombosis is thus distinct from other venous thromboembolic disorders. 
Doppler ultrasonography is the preferred initial test, while contrast venography remains the gold 
standard for diagnosis. Computed tomographic venography and magnetic resonance venography 
are comparable to conventional venography and are being increasingly used. Conservative 
management with anticoagulation alone is inadequate and leads to significant residual disability. 
An aggressive multimodal treatment strategy consisting of catheter-directed thrombolysis, with or 
without early thoracic outlet decompression, is essential for optimizing outcomes. Despite excellent 
insights into its pathogenesis and advances in treatment, a significant number of patients with 
effort thrombosis continue to be treated suboptimally. Hence, there is an urgent need for increasing 
physician awareness about risk factors, etiology and the management of this unique and relatively 
infrequent disorder. [West J Emerg Med. 2010; 11(4):358-362.]
INTRODUCTION
Effort thrombosis refers to axillary-subclavian vein 
thrombosis (ASVT) associated with strenuous and repetitive 
activity of the upper extremities. The earliest description of 
spontaneous ASVT was by Cruveilhier in 1816, and the first 
elaborate account was provided by James Paget in 1875.1,2 In 
1894, von Schroetter was the first to identify vascular trauma 
from muscle strain as a potential etiologic factor.3 In 1948, 
Hughes coined the term Paget-Schroetter Syndrome (PSS) 
and published the first review.4, 5 PSS accounts for 30- 40 % 
of spontaneous ASVT and for 10-20 % of all upper extremity 
deep venous thrombosis (UEDVT). 6 Other important 
predisposing factors for UEDVT include indwelling hardware 
(central venous catheter, ports, and pacemakers), occult or 
overt malignancy and other thrombophilic states. 6-10 
PATHOGENESIS
Effort thrombosis usually follows sporting activities, such 
as wrestling, playing ball, gymnastics and swimming, which 
involve vigorous and sustained upper extremity movements.11 
It is believed that retroversion, hyperabduction and extension 
of the arm involved with these activities impose undue strain 
on the subclavian vein leading to microtrauma of the 
endothelium and activation of the coagulation cascade. 
Substantial evidence now supports the role of anatomical 
abnormalities involving the thoracic outlet (cervical rib, 
congenital bands, hypertrophy of scalenus tendons and 
abnormal insertion of the costoclavicular ligament) in the 
pathogenesis of effort thrombosis. 11, 12 (Figures 1 and 2 depict 
the normal/abnormal anatomy of the thoracic outlet.) The 
narrow costoclavicular space leads to compression of the vein Volume XI, no. 4  :  September 2010  359  Western Journal of Emergency Medicine
and to stasis in the flow. More importantly, it restricts the 
mobility of the subclavian vein, making it more susceptible to 
trauma from arm use. These lead to a self-perpetuating cycle 
of endothelial trauma, thrombosis and recanalization. The 
repetitive endothelial trauma leads to intimal hyperplasia, 
inflammation and fibrosis, resulting in venous webs, extensive 
collateral formation and perivenular fibrosis. This in turn 
worsens the stasis and costoclavicular crowding. Effort 
thrombosis has therefore been rightfully categorized as a 
venous variant of thoracic outlet syndrome. 12, 13
Some investigators have reported a higher frequency 
of factor V Leidin, Prothrombin gene mutation and other 
inherited thrombophilic states in patients with idiopathic 
UEDVT.14 -16 In fact, in one recent study, Cassada et al. 
demonstrated that approximately two-thirds of patients with 
PSS had concurrent thrombophilia. 17 In addition, they showed 
that concurrent thrombophilia led to increased postoperative 
complications following corrective surgery. However, others 
have refuted this association by demonstrating that the 
frequency of inherited thrombophilias in patients with effort 
thromboses was comparable to that of the general population. 
They found that the increased frequency of concurrent 
thrombophilic disorders was limited to patients with idiopathic 
UEDVT, which was not effort related.18 Thus, unlike venous 
thromboses elsewhere (lower extremities and visceral), 
the role of inherited and acquired thrombophilic disorders 
in the development and progression of effort thrombosis 
is unclear. In summary, costoclavicular crowding due to 
anatomical abnormalities and repetitive endothelial trauma 
from muscular strain are the key pathogenic factors in the 
initiation and progression of effort thrombosis. Inflammation, 
by leading to perivenular fibrosis and adhesions, seems to play 
a contributory role in the perpetuation of obstruction. The role 
of inherited and acquired thrombophilic disorders remains 
unresolved and needs further investigation.
CLINICAL FEATURES 
 Not surprisingly, effort thrombosis is more common in 
young and otherwise healthy men. It preferentially involves 
the dominant arm. Unlike those with UEDVT secondary to 
central venous catheters, patients with effort thrombosis are 
usually symptomatic. Swelling and arm discomfort are the 
most frequent presenting problems.12, 13, 19 Other symptoms 
include heaviness, redness of arm, cyanosis and dilated, 
visible veins across the shoulder and upper arm (Urschel’s 
sign).12 Symptom onset is usually acute or sub-acute but an 
occasional patient can present with chronic symptoms. Not 
infrequently, symptoms can be nonspecific and can even 
mimic a muscular strain.20 A majority of patients report 
a discrete precipitating event, usually sports-related arm 
exertion. Occasionally, minor and relatively innocuous 
day-to-day activities can precipitate effort thrombosis.11, 
12 Complications include pulmonary embolism, post-
thrombotic syndrome and recurrent thrombosis.12, 13 While 
some investigators report a lower incidence of pulmonary 
embolism compared to patients with lower extremity DVT 
Figure	2. Abnormal lateral insertion of the costoclavicular liga-
ment in Paget-Schroetter syndrome. Foot note: Reproduced with 
permission from Urschel et al, Ann Thorac Surg 2008;86:254-60 12 
Copyright Elsevier Inc, 2008. 
Figure	1. Normal anatomy of the thoracic outlet. Foot note: 
Reproduced with permission from Urschel et al, Ann Thorac Surg 
2008;86:254-60 12 Copyright Elsevier Inc, 2008. 
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and catheter related UEDVT, others have refuted this.19, 21, 22 
Irrespective of the relative risk, it is important to bear in mind 
that the risk of pulmonary embolism with effort thrombosis is 
real and significant. Post-thrombotic syndrome (characterized 
by pain, heaviness, and swelling), on the other hand, is more 
frequent in effort thrombosis, compared to secondary UEDVT, 
and is the major contributor to the morbidity associated with 
disease.12, 13, 23, 24 In one recent review, it was shown that up to 
45% (15% on average) with UEDVT develop post-thrombotic 
syndrome. 24 The fact that effort thrombosis preferentially 
affects young and active individuals makes even minor 
degrees of residual disability very relevant.
DIAGNOSIS
Notably, the symptoms and signs of UEDVT have 
poor specificity, and less than 50% of those with suggestive 
symptoms actually have deep venous thrombosis (DVT). 
12, 13, 25 Confirmatory tests are therefore crucial following 
a presumptive clinical diagnosis.23, 25 Compression 
ultrasonography with color Doppler by virtue of its ease, 
availability, portability and low cost is currently the preferred 
initial test in the evaluation of suspected UEDVT.26 Contrast 
venography has traditionally been the gold standard for 
the diagnosis of UEDVT. However, invasive nature, high 
cost, and the accuracy of non-invasive tests have relegated 
venography to the background.12, 13, 27, 28 Radionuclide, 
magnetic resonance and computed tomographic venography 
are superior to ultrasonography. Magnetic resonance 
venography has the highest sensitivity (100%) and specificity 
(97%) among all the non-invasive diagnostic modalities and 
has the potential to replace digital subtraction angiography 
as the gold standard.27 However, the higher cost and limited 
availability limits the applicability of magnetic resonance 
venography.12, 13, 22, 26- 28 Conversely, computed tomographic 
venography is widely available but is associated with risks 
of radio contrast administration. These tests are therefore 
second line and reserved for patients with high clinical 
probability of effort thrombosis and negative ultrasound. 
Though venography is not necessary for diagnosis, it is almost 
always done as a part of multimodal treatment strategy to 
deliver catheter-directed thrombolysis and plan thoracic outlet 
decompression surgery. 12
MANAGEMENT
Contemporary management of effort thrombosis varies 
widely, and there is no broad consensus as to what constitutes 
the best approach. The relative rarity of the disease, paucity of 
awareness and lack of large randomized trails are factors 
contributing to this confusion. For many years patients with 
effort thrombosis were managed conservatively with limb 
elevation and anticoagulation alone. However, subsequent 
long-term data demonstrated an unacceptably high incidence 
of residual symptoms, disability and recurrent thrombosis with 
this conservative strategy.12, 29-31 This has prompted clinicians 
to devise and evaluate aggressive treatment strategies 
involving thrombolysis, thrombectomy, percutaneous and 
surgical venoplasty, venous bypass and stents. 
Systemic fibrinolysis is superior to anticoagulation in 
achieving vein patency but is associated with higher rates of 
complications such as intracranial hemorrhage.32 Local 
catheter-directed thrombolysis has the therapeutic value of 
systemic thrombolysis without significant systemic side 
effects and is currently recommended in all patients presenting 
early.33 The precise time interval for defining early 
presentation is unclear. While some authors recommend using 
fibrinolytics only in patients presenting within two weeks of 
symptom onset, others have reported fair outcomes even with 
a delay of about four to six weeks.12, 34-36 Of note, the success 
of thrombolysis diminishes as the time from symptom onset to 
treatment increases, underscoring the need for prompt 
recognition and treatment.12 Newer fibrinolytics like alteplase 
and reteplase have replaced urokinase and streptokinase due to 
their better safety profile. The duration of treatment and dose 
of these agents is not standardized and therefore varies among 
various institutions. Most patients require prolonged infusion 
of the fibrinolytic agent for catheter directed thrombolysis; 
average durations varying between 24-48 hours.33 
Therapy directed at thoracic outlet decompression (TOD) 
has become an integral part in the management of effort 
thrombosis with the recognition of the central role of thoracic 
outlet obstruction. TOD involves resection of the first rib, 
division of the scalenus muscles and the costoclavicular 
ligament using either a transaxillary or infraclavicular 
approach. Some investigators reserve TOD only for patients 
with persistent or recurrent symptoms following catheter-
directed thrombolysis. Lee et al. used this restrictive 
strategy and reported that less than 25% of patients needed 
surgery after a mean follow up of 13 months. 37 However, 
others recommend routine and early TOD in all patients.36, 
38 Suboptimal results with delayed surgery vis-à-vis early 
surgery; in the form of higher incidence of residual symptoms, 
disability from post-thrombotic syndrome and recurrent 
thrombosis, argue in favor of early TOD.34-36 Controversy 
remains regarding the best surgical approach to achieve TOD. 
Some suggest that the anterior, or sub-clavicular, approach 
is superior because it allows better exposure of the proximal 
subclavian and innominate veins, thereby ensuring more 
optimal vein repair.36 However, others have reported excellent 
results with the relatively easier transaxillary approach.12 
Either approach can be associated with complications like 
pneumothorax, bleeding, nerve or arterial injury, underscoring 
the need for careful patient selection. Moreover, thoracic 
outlet decompression is a complicated surgery and should 
be undertaken only by experienced surgeons at centers 
with expertise in managing patients of effort thrombosis. 
The need for a detailed discussion with patients regarding 
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the risks and benefits of surgery cannot be overstated. So 
far, definite markers predicting failure of thrombolysis and 
need for surgery have not been identified. Lee et al. reported 
that age < 28 years was a predictor of recurrent thrombosis 
following thrombolysis.37 However, further validation is 
awaited. Surgical thrombectomy, balloon venoplasty and 
stenting have practically been abandoned due to the limited 
success, high procedural morbidity, and high rates of stent 
fracture.12, 36-38 Patch venoplasty and venous bypass have 
been successfully used in some patients with residual 
stenosis after TOD.35, 36 Based on our own experience and 
review of the literature, we suggest the algorithm in Figure 
3 as a guide to the diagnosis and management of patients 
with suspected effort thrombosis. It is reasonable to seek 
early surgical (vascular and thoracic) consultation in all 
young patients with UEDVT especially, in the absence of 
obvious precipitating factors, such as a central venous line. 
Finally, the need for and the duration of anticoagulation 
in patients treated with a combination of catheter-directed 
thrombolyis and TOD remains unclear. While some authors 
recommend no anticoagulation when good surgical results 
are obtained, others prefer anticoagulation for at least two to 
three months12, 36 As already mentioned, the role of inherited 
and acquired thrombophilic states in effort thrombosis is 
unclear. Nevertheless, it is reasonable to test at least selected 
patients for these abnormalities as they might help predict 
postoperative complications, recurrence rates and determine 
the need for long-term anticoagulation. It appears reasonable 
to recommend long-term anticoagulation in patients with 
coexistent thrombophilias and for those presenting late and 
having suboptimal surgical results. However, the efficacy of 
this strategy in preventing recurrent thrombosis and alleviating 
symptoms is unclear and needs further study.  
CONCLUSION
In summary, effort thrombosis is a complex and 
relatively infrequent disorder with a distinct pathogenesis. 
Most physicians unfamiliar with effort thrombosis manage 
it similarly to classic lower extremity DVT. Instead, effort 
thrombosis is ideally managed using a multimodal approach 
consisting of routine catheter-directed thrombolysis, early 
TOD in appropriate patients and physical and occupational 
therapy. Long-term anticoagulation may be reasonable 
in patients with coexistent thrombophilia and suboptimal 
surgical results. Increasing awareness among primary care and 
emergency physicians will ensure early recognition, timely 
thrombolysis, and prompt referral to a thoracic or vascular 
surgeon. Future research should focus on defining the benefit 
of thrombolytic therapy in patients presenting late, identifying 
factors that predict failure of thrombolysis and need for 
surgery. Other avenues for research include assessment of the 
need for and duration of anticoagulation following TOD, and 
cost benefit analysis of the various treatment strategies. 
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